The Relationship Between The Snp Of ERCC1 In Peripheral Blood Of Nsclc And The Effects Of Cisplatinum-based Chemotherapy

BACKGROUND:Nowadays lung cancer is the most common malignant neoplasm in the world , of which both the morbidity and mortality are at the top. Similarly ,in recent years,both morbidity and mortality of lung cancer are also increasing rapidly in China,rising to the first cancer-related deaths,five years suvival rate of which is about 15%. About 80-85% of those lung cancer patients is classified as non-small cell lung cancer(NSCLC),but probably 70-80% of the patients had developed to advanced stage when they were diagnosed,so so it's a pity that they lost the opportunity to receive surgery treatment. Chemotherapy has been one of the three major clinically treatment with lung cancer.The effective rate of the commonly used chemotherapy regimens of lung cancer is only 30-50% at present,resulting in that more than half of the lung cancer patients cannot benefit from the treatment,and the accompany treatment is harmful to them.Consequently, individual chemotherapy has very important clinical significance.In recent years,with the 3rd generation of chemotherapy drugs widely used in clinic,platinum combination with the 3rd generation chemotherapy drugs has gradually been the standard chemotherapy regimens in lung cancer,but the effective rate only about 30%. The occurrence of platinum resistance has bebome one of the major obstacles and bring poor prognosis to NSCLC patients.ERCC1 is a component of the nucleotice excision repair(NER) pathway,which is essential for the repair of platinum-DNA adducts and is associated with cellular resistance to platinum compounds.Cancer cells that overexpress ERCC1 are more likely to have resistance to platinum compounds.Patients with low level of ERCC1 mRNA expression had significantly longer survival.Some researches estimate the 118th codon SNP of ERCC1 can influence the effect of platinun-based chemotherapy through the diffenent level of ERCC1 mRNA expression.OBJECTIVE:To determine the relationship between the SNP of ERCC1 118th codon and the effects of cisplatin-based chemotherapy in non-small cell lung cancer(NSCLC).METHODS:Collect the the peripheral anticoagulation blood of NSCLC patients and clinical data, and then extract EDTA-K2cnticoagulant blood DNA according to the examine the genomic DNA extraction kit instruction.Apply fluorescence polarization detection(FP assay) to detect 118th codon SNP of ERCC1 of the peripheral blood of 60 non-small cell lung cancer patients ,and study the relationship with the effienct of cisplatin-based chemotherapy.RESULTS:The results showed tha the 118th codon SNP of ERCC1 hadn't been any association with patient age, gender, histology types ,smoking history, and clinical stages (P>0.05). The response rate of variant form C/T+T/T patients was 20%(5/25),and the response rate of cisplatin-based chemotherapy in C/C gene type patients was 48.6%(17/35).There was a significant difference (χ2=5.27,P<0.05).CONCLUSION:The 118 codon SNP of ERCC1 of NSCLC may be associated with the response of cisplatinum-based chemotherapy.